MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The proposed study is a two-step trial with 1) a safety run in part conducted in pediatric
patients and 2) a Phase II part in adult and pediatric patients aiming to evaluate the safety
and clinical activity of atezolizumab + cobimetinib in advanced/metastatic soft tissue
sarcomas.